Top Markets
#1 Siren Siren +34.29%
#2 Wiki Cat Wiki Cat +29.28%
#3 Bitway Bitway +20.25%
#4 Ribbita by Virtuals Ribbita by Virtuals +19.79%
#5 TRIA TRIA +17.08%
#6 PulseChain PulseChain +16.92%
#7 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.84%
#8 Velvet Velvet +15.27%
#9 Cysic Cysic +14.22%
#10 The Grays Currency The Grays Currency +14.20%
Coin of the day
Siren Siren
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Clasificación en acciones #30838
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Precio por acción
$0.089
Última sincronización: 2026-08-17
Capitalización bursátil
$15.36M
Cambio (1 día)
50.59%
Cambio (1 año)
111.85%
País
US
Comercio Inhibitor Therapeutics, Inc. (INTI)

Categoría

Healthcare
Ganancias de Inhibitor Therapeutics, Inc. (INTI)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Inhibitor Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Inhibitor Therapeutics, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE